Page last updated: 2024-11-07

fe(ii)-edta

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Fe(II)-EDTA, also known as ferrous ethylenediaminetetraacetic acid, is a coordination complex formed by the interaction of ferrous ions (Fe2+) with the chelating agent ethylenediaminetetraacetic acid (EDTA). It is a stable complex that is commonly used in various applications, including:

* **Synthesis:** Fe(II)-EDTA is typically synthesized by reacting ferrous sulfate (FeSO4) with EDTA in an aqueous solution. The reaction proceeds under mild conditions, and the resulting complex can be isolated as a solid or used directly in solution.
* **Effects:** Fe(II)-EDTA is known for its chelating properties, which allow it to bind to metal ions and prevent their interaction with other molecules. This property makes it useful for various applications, including:
* **Iron supplementation:** Fe(II)-EDTA is used as an iron supplement, as it helps improve iron absorption and bioavailability in the body.
* **Treatment of iron overload:** In cases of iron overload, Fe(II)-EDTA can be used to chelate excess iron from the body.
* **Antioxidant activity:** Fe(II)-EDTA has been shown to exhibit antioxidant activity, protecting cells from oxidative damage.
* **Importance:** Fe(II)-EDTA plays a crucial role in several biological processes, including:
* **Iron metabolism:** Fe(II)-EDTA facilitates the transport and utilization of iron in the body.
* **Red blood cell formation:** Iron is essential for the synthesis of hemoglobin, which is responsible for oxygen transport in the blood. Fe(II)-EDTA contributes to this process by providing readily available iron for hemoglobin synthesis.
* **Research:** Fe(II)-EDTA continues to be studied for its potential applications in:
* **Medical research:** Investigating its efficacy in treating iron deficiency, iron overload, and other medical conditions.
* **Environmental studies:** Evaluating its impact on the environment and its potential for remediation of heavy metal contamination.
* **Biotechnology:** Exploring its potential use in bioremediation and biosensing applications.'

Fe(II)-EDTA: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID115140
CHEBI ID30730
MeSH IDM0156320

Synonyms (17)

Synonym
(ethane-1,2-diyldinitrilo)tetraacetatoferrate(ii)
[fe(edta)](2-)
iron(ii)-edta
(ethane-1,2-diyldinitrilo)tetraacetatoferrate(2-)
15651-72-6
fe(ii)-edta
ethylenediaminetetraacetatoferrate(2-)
CHEBI:30730 ,
56174-59-5
edta fe(ii)
ferrate(2-), ((n,n'-1,2-ethanediylbis(n-((carboxy-kappao)methyl)glycinato-kappan,kappao))(4-))-, (oc-6-21)-
ferrate(2-), ((n,n'-1,2-ethanediylbis(n-(carboxymethyl)glycinato))(4-)-n,n',o,o',on,on')-, (oc-6-21)-
ferrate(2-), ((n,n'-1,2-ethanediylbis(n-((carboxy-kappao)methyl)glycinato-kappan,kappao))(4-))-, diammonium, (oc-6-21)-
ferrate(2-), ((n,n'-1,2-ethanediylbis(n-((carboxy-kappao)methyl)glycinato-kappan,kappao))(4-))-, ammonium (1:2), (oc-6-21)-
ferrate(2-), [[n,n'-1,2-ethanediylbis[n-[(carboxy-.kappa.o)methyl]glycinato-.kappa.n,.kappa.o]](4-)]-, diammonium, (oc-6-21)-
Q27113964
2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;iron(2+)

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Na2EDTA, added to food to prevent oxidation, enhances iron bioavailability by chelating added iron."( EDTA and the absorption of iron from food.
Bothwell, TH; Lamparelli, RD; MacPhail, AP; Patel, RC, 1994
)
0.29

Dosage Studied

ExcerptRelevanceReference
" Sulfide, either dosed externally or formed during the batch incubation out of endogenous sulfur sources or the supplied sulfate or sulfite, influences the production and consumption of the intermediate nitrous oxide (N2O) during Fe(II)EDTA2- bound NO reduction."( Effect of sulfur compounds on biological reduction of nitric oxide in aqueous Fe(II)EDTA2- solutions.
Lens, PN; Manconi, I; van der Maas, P, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
iron coordination entity
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (108)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (4.63)18.7374
1990's45 (41.67)18.2507
2000's31 (28.70)29.6817
2010's25 (23.15)24.3611
2020's2 (1.85)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.49 (24.57)
Research Supply Index4.73 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index29.80 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.89%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other111 (99.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]